Covid Rebound with Pfizer’s Paxlovid Less Than Expected

(Bloomberg) On the (Paxlovid) rebound, Pfizer Inc.’s antiviral medication caused recurrences or prolonged infections more often in real life than in clinical studies. (A rebound of coronavirus occurred in 2.3% of patients on Paxlovid versus 1.7% receiving placebo in a late-stage trial, Pfizer scientists said in September.)